![Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol](https://bmjopen.bmj.com/content/bmjopen/3/7/e002902/F1.large.jpg)
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol
![ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma](https://www.urotoday.com/images/atlas_trial_schema.png)
ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma
PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy | tctmd.com
![Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial | Trials | Full Text Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial | Trials | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13063-020-04637-z/MediaObjects/13063_2020_4637_Fig1_HTML.png)
Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial | Trials | Full Text
![Drug trials Learning Outcome: DESCRIBE THE USE OF OPEN LABEL, BLIND AND DOUBLE BLIND TESTS IN HUMAN TRIALS (HIGHER) AND THE USE OF PLACEBOS. - ppt download Drug trials Learning Outcome: DESCRIBE THE USE OF OPEN LABEL, BLIND AND DOUBLE BLIND TESTS IN HUMAN TRIALS (HIGHER) AND THE USE OF PLACEBOS. - ppt download](https://images.slideplayer.com/20/6050871/slides/slide_6.jpg)
Drug trials Learning Outcome: DESCRIBE THE USE OF OPEN LABEL, BLIND AND DOUBLE BLIND TESTS IN HUMAN TRIALS (HIGHER) AND THE USE OF PLACEBOS. - ppt download
![Headache Journal on Twitter: "Transcranial Magnetic Stimulation for #Migraine Prevention in #Adolescents: A Pilot Open-Label Study #TMS SL Irwin et al @aagelfand @petergoadsby https://t.co/ThCNhNnWbu https://t.co/eummTQHnsY" / Twitter Headache Journal on Twitter: "Transcranial Magnetic Stimulation for #Migraine Prevention in #Adolescents: A Pilot Open-Label Study #TMS SL Irwin et al @aagelfand @petergoadsby https://t.co/ThCNhNnWbu https://t.co/eummTQHnsY" / Twitter](https://pbs.twimg.com/media/DYMn_dNWkAA0P_E.jpg)
Headache Journal on Twitter: "Transcranial Magnetic Stimulation for #Migraine Prevention in #Adolescents: A Pilot Open-Label Study #TMS SL Irwin et al @aagelfand @petergoadsby https://t.co/ThCNhNnWbu https://t.co/eummTQHnsY" / Twitter
![Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa - Journal of the American Academy of Dermatology Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e4db88a9-95c1-49d9-98d9-d8fb1d6d9d68/gr1.jpg)
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa - Journal of the American Academy of Dermatology
![PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/814ad6ccbfa9defca4d2b00c4672f9070cf6b8da/16-Figure1-1.png)
PDF] Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. | Semantic Scholar
![An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-019-1857-3/MediaObjects/13075_2019_1857_Fig1_HTML.png)
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
![Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2080812205/2072208225/gr1.jpg)
Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition - Journal of Clinical Epidemiology
![Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f5b9964c-4331-4321-a712-8d6a65155a91/gr1_lrg.jpg)
Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial - Seizure - European Journal of Epilepsy
![A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41436-020-01006-8/MediaObjects/41436_2020_1006_Fig1_HTML.png)